年内多只绩优基金频频限购

Group 1 - Central viewpoint: Several mutual funds in China are implementing purchase limits to ensure stable operations and protect the interests of fund shareholders [1][2][7] - The China Europe Fund announced a limit of 100,000 yuan for the China Europe Medical Innovation fund managed by manager Ge Lan, effective from August 11 [1] - The China Europe Science and Technology Innovation fund managed by manager Shao Jie also announced a limit of 1 million yuan, effective from the same date [2] Group 2 - As of August 6, the China Europe Medical Innovation fund achieved a one-year return of 85.03%, ranking in the top 2 of its category [2] - The China Europe Science and Technology Innovation fund reported a one-year return of 88.5%, also ranking in the top 2 [2] - Approximately 50 actively managed equity funds have announced purchase limits since the beginning of the second half of the year, reflecting a trend in the domestic equity market [2][7] Group 3 - The strong performance of the Hong Kong innovative pharmaceutical sector has been a key driver for the "doubling funds" [3] - Several funds, including the China Hong Kong Pharmaceutical Fund, have reported year-to-date net value growth rates exceeding 100% [3] - QDII funds with excellent market returns are also announcing restrictions on large purchases and regular investment plans [5][6] Group 4 - The main reasons for these purchase restrictions include protecting the interests of fund shareholders and ensuring stable fund operations [7] - Industry experts believe that proactive purchase limits during favorable market conditions can help maintain the effectiveness of investment strategies and protect existing shareholders' interests [7]